Daiichi Sankyo has started patient enrollment for two late-stage trials of nimotuzumab, its experimental drug for lung and gastric cancer. Nimotuzumab is a recombinant humanized monoclonal antibody that targets the epidermal growth factor receptor. The lung cancer trial will be carried out in Japan while the gastric cancer study will be conducted in Japan and South Korea.

Related Summaries